Medicamen Biotech Limited (BOM:531146)
India
· Delayed Price · Currency is INR 285.50
-6.00 (-2.06%)
At close: Mar 9, 2026
Medicamen Biotech Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Market Capitalization | 3,630 | 6,125 | 4,871 | 8,293 | 7,864 | 6,524 | Upgrade
|
| Market Cap Growth | -39.20% | 25.74% | -41.27% | 5.46% | 20.54% | 195.52% | Upgrade
|
| Enterprise Value | 3,580 | 6,262 | 5,027 | 8,273 | 8,078 | 6,675 | Upgrade
|
| Last Close Price | 285.50 | 480.26 | 381.13 | 651.22 | 638.84 | 529.12 | Upgrade
|
| PE Ratio | 48.86 | 86.16 | 44.56 | 55.87 | 52.79 | 53.78 | Upgrade
|
| PS Ratio | 2.11 | 3.66 | 2.72 | 5.89 | 6.81 | 5.79 | Upgrade
|
| PB Ratio | 1.32 | 2.88 | 2.35 | 4.29 | 5.37 | 4.91 | Upgrade
|
| P/TBV Ratio | 1.32 | 2.90 | 2.38 | 4.34 | 5.38 | 4.92 | Upgrade
|
| P/OCF Ratio | - | - | - | - | 191.38 | 51.08 | Upgrade
|
| EV/Sales Ratio | 2.08 | 3.74 | 2.80 | 5.87 | 7.00 | 5.92 | Upgrade
|
| EV/EBITDA Ratio | 19.00 | 33.48 | 22.67 | 34.63 | 34.27 | 34.62 | Upgrade
|
| EV/EBIT Ratio | 29.99 | 53.10 | 32.95 | 46.92 | 45.14 | 39.67 | Upgrade
|
| Debt / Equity Ratio | 0.14 | 0.16 | 0.15 | 0.13 | 0.18 | 0.14 | Upgrade
|
| Debt / EBITDA Ratio | 2.05 | 1.81 | 1.40 | 1.08 | 1.09 | 0.98 | Upgrade
|
| Net Debt / Equity Ratio | -0.02 | 0.14 | 0.08 | 0.03 | 0.15 | 0.11 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.27 | 1.61 | 0.74 | 0.21 | 0.93 | 0.77 | Upgrade
|
| Net Debt / FCF Ratio | - | -2.90 | -1.25 | -0.38 | -4.88 | -2.87 | Upgrade
|
| Asset Turnover | - | 0.57 | 0.63 | 0.56 | 0.55 | 0.60 | Upgrade
|
| Inventory Turnover | - | 1.42 | 1.80 | 2.04 | 3.37 | 6.42 | Upgrade
|
| Quick Ratio | - | 1.25 | 1.09 | 1.31 | 1.19 | 1.48 | Upgrade
|
| Current Ratio | - | 2.11 | 1.89 | 1.98 | 1.69 | 1.80 | Upgrade
|
| Return on Equity (ROE) | - | 3.12% | 4.74% | 8.67% | 10.67% | 9.55% | Upgrade
|
| Return on Assets (ROA) | - | 2.49% | 3.33% | 4.37% | 5.33% | 5.61% | Upgrade
|
| Return on Invested Capital (ROIC) | 3.38% | 3.36% | 5.25% | 8.31% | 9.32% | 8.97% | Upgrade
|
| Return on Capital Employed (ROCE) | - | 5.40% | 7.30% | 9.00% | 11.70% | 12.00% | Upgrade
|
| Earnings Yield | 2.14% | 1.16% | 2.24% | 1.79% | 1.89% | 1.86% | Upgrade
|
| FCF Yield | - | -1.69% | -2.67% | -1.55% | -0.57% | -0.80% | Upgrade
|
| Dividend Yield | 0.34% | 0.21% | 0.26% | 0.15% | 0.16% | 0.19% | Upgrade
|
| Payout Ratio | - | 17.89% | 11.57% | 8.52% | 8.20% | 5.04% | Upgrade
|
| Buyback Yield / Dilution | -9.75% | -0.44% | -0.07% | -3.56% | - | -0.56% | Upgrade
|
| Total Shareholder Return | -9.41% | -0.23% | 0.20% | -3.40% | 0.16% | -0.37% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.